Xeloda Market: By Type (500mg and 150mg), By Application (Colon Cancer, Rectal Cancer, Breast Cancer, Gastric Cancer, and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), and Geography

Xeloda's market size was valued at USD 419.3 million in 2023 and is poised to grow at 5.7 % CAGR from 2024 to 2030. Xeloda is a brand-name prescription medication used to treat certain forms of cancer in adults. Specifically, Xeloda also known as “Capecitabine” is approved to treat: Metastatic breast cancer. With metastatic breast cancer, breast cancer has spread to other parts of the body. The growth of the Xeloda market rose to the rising cases of cancer worldwide, increasing demand for targeted drugs to lower the massive side effects drive the market. According to the American Cancer Society Report, it is estimated in 2019, there will be 1,762,450 new cancer cases diagnosed and 606,880 cancer deaths in the United States.

Increased deaths encourage key players towards research and development of new products and launches which create major opportunities in the Capecitabine market. lack of trained professionals and high cost of treatment hamper the market growth, which creates hindrances in the treatment. According to WHO, Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths, cancer-causing infections, such as human papillomavirus (HPV) and hepatitis, are responsible for approximately 30% of cancer cases in low- and lower-middle-income countries. Geographically, North America held the major market share in 2022 and is expected to dominate the global embolization market in the forecasted years.

Xeloda Market Key Developments:

• In December 2022, the FDA approved updated drug labeling including new indications and dosing regimens for Xeloda (capecitabine) tablets, under Project Renewal, an Oncology Center of Excellence initiative aimed at updating labeling information for certain older oncology drugs to ensure information is clinically meaningful and scientifically up to date. This is the first drug to receive a labeling update under this pilot program.
• In April 2022, Cheplapharm Arzneimittel GmbH (“Cheplapharm”) signed an agreement with F. Hoffmann-La Roche Ltd. to acquire the worldwide rights to Xeloda® (capecitabine). Under the terms of the agreement, Cheplapharm will receive product rights for Xeloda® in certain countries worldwide including the USA.